In addition, we have shown that treatment more significantly induces the recovery of circulating CD1c+ cDC and that this is associated with clinical improvement, supporting that these cells actively contribute to chronicity of RA pathology. This evidence concerns the gene CD1C and rheumatoid arthritis.